Last reviewed · How we verify
Albiglutide weekly injection
GLP-1 receptor agonist
GLP-1 receptor agonist Used for Type 2 diabetes.
At a glance
| Generic name | Albiglutide weekly injection |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
Albiglutide works by activating the glucagon-like peptide-1 (GLP-1) receptor, which helps to lower blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus (PHASE3)
- An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects (PHASE4)
- Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus (PHASE2)
- Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus (PHASE3)
- Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects (PHASE4)
- Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus (PHASE4)
- A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |